Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer

Nivolumab is an immune checkpoint inhibitor with demonstrated efficacy against several malignant tumors. Alterations in driver oncogenes such as EGFR and ALK are a poor prognostic factor in nivolumab therapy for non-small cell lung cancer (NSCLC), whereas a smoking history is a well-known, favorable...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Case Rep Oncol
Main Authors: Yamasaki, Masahiro, Saito, Naomi, Hada, Yu, Miyamoto, Sayaka, Okanobu, Hideharu, Ikeda, Naoya, Daido, Wakako, Ishiyama, Sayaka, Deguchi, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki
Formato: Artigo
Idioma:Inglês
Publicado: S. Karger AG 2017
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436064/
https://ncbi.nlm.nih.gov/pubmed/28559820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000470830
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares